Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

638.20INR
23 May 2018
Change (% chg)

Rs-6.85 (-1.06%)
Prev Close
Rs645.05
Open
Rs644.00
Day's High
Rs649.40
Day's Low
Rs633.50
Volume
1,113,875
Avg. Vol
2,750,149
52-wk High
Rs677.90
52-wk Low
Rs295.03

Select another date:

Wed, May 2 2018

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

India's Biocon Q4 profit rises 2.2 pct

April 26 Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

BRIEF-Mylan, Biocon get approvals from European Commission, TGA Australia for Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE APPROVALS FROM THE EUROPEAN COMMISSION AND TGA AUSTRALIA FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE Source text for Eikon: Further company coverage:

BRIEF-India's Biocon ‍Says U.S. FDA Completed Pre-Approval Inspection At Malaysia Unit ​

* ‍U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT MALAYSIA FACILITY AND ISSUED FORM 483 WITH 6 OBSERVATIONS​ Source text - http://bit.ly/2EUL56I Further company coverage:

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

India's Biocon Q3 profit plunges 46 pct

Jan 24 Biocon Ltd, India's biggest biotechnology firm, posted a 46 percent fall in third-quarter profit on Wednesday hurt by an increase in interest and depreciation costs related to its Malaysia operations.

BRIEF-India's Biocon Dec-Qtr Consol Profit Down About 46 pct

* DEC QUARTER CONSOL PROFIT 919 MILLION RUPEES VERSUS 1.71 BILLION RUPEES LAST YEAR

Select another date: